Skip to main content
. 2017 Apr 27;8(26):42742–42751. doi: 10.18632/oncotarget.17451

Figure 3. H2-18 inhibits the downstream signaling pathways of ErbB2 in NCI-N87 cells but not in NCI-N87-TraRT cells.

Figure 3

Immunoblots assessing the effect of control IgG (NEG), trastuzumab, pertuzumab, trastuzumab plus pertuzumab, and H2-18 on ErbB2 signaling changes in NCI-N87 and NCI-N87-TraRT cell lines. Every experiment was repeated 3 times.